tubulin beta 2B class IIb pseudogene 1Genealiases: []
Q-omics provides the consensus-scored TUBB2BP1 profile across patient tissues and cancer cell-line models. TUBB2BP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TUBB2BP1 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, TUBB2BP1 RNA expression shows 10,826 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, BRCA, and TGCT as cancer lineages where TUBB2BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB2BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB2BP1 survival associations across molecular data types. TUBB2BP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB2BP1 RNA expression–survival associations across cancer types. High TUBB2BP1 expression shows unfavorable associations in READ, ACC, BLCA, THCA, UCEC and ESCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for TUBB2BP1 RNA expression.
This table summarizes TUBB2BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TUBB2BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB2BP1 shows lower tumor expression in BRCA and KIRC and higher tumor expression in LIHC, LUSC, LUAD and PRAD. The BRCA box plot shows higher TUBB2BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p < 0.001).
This table shows molecular features associated with TUBB2BP1 in patient tissues and cancer cell lines. In patient samples, TUBB2BP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
